Viron reports positive proof of concept results in arthritis for its VT-346 anti-TNF therapeutic

18-Mar-2010 - Canada

Viron Therapeutics Inc. announced that VT-346, an anti-TNF protein therapeutic, demonstrated positive results in a pivotal proof of concept study in the gold standard transgenic mouse model for arthritis. VT-346 achieved a statistically significant, dose dependent impact in this preclinical model of arthritis and prevented deterioration due to disease in terms of weight gain, arthritic score and pathology parameters. VT-346 had particularly strong protective effects on therapeutically-important bone and cartilage damage in this model. The target for VT-346 is the inflammatory cytokine TNF, which is also the target for several biological therapies whose annual sales are expected to top $20 billion in 2010, making anti-TNF therapies the most commercially successful single-target group of biological therapies. Notable, however, is VT-346's unique method of neutralizing TNF, an important mediator of inflammation and therapeutic target in diseases including rheumatoid arthritis, Alzheimer's disease and Crohn's disease.

"The development of an anti-TNF therapy that is fundamentally different from existing therapies offers hope to patients that do not respond adequately to existing anti-TNF drugs," said Dr. Edward Keystone, Head of the Rebecca MacDonald Centre for Arthritis and Autoimmune Diseases and a recognized leader in the development of drugs targeting rheumatoid arthritis. "Approximately 30-50% of patients do not respond optimally to currently available anti-TNF therapies. The potency in pre-clinical studies and unique mechanism by which VT-346 functions could allow clinicians to achieve better outcomes in these patients."

Viron researchers selected this animal model of arthritis due to its accurate prediction of clinical benefits for the currently marketed anti-TNF therapeutics. These animal model results build on early pre-clinical in vitro testing and characterization of this compound that was conducted using human tissues to demonstrate potent anti-inflammatory activities. Studies were conducted by BioMedCode, a recognized leader in the use of this transgenic model.

https://www.bionity.com/en/news/115067/viron-reports-positive-proof-of-concept-results-in-arthritis-for-its-vt-346-anti-tnf-therapeutic.html